Adalimumab demonstrates continued safety and acceptability with long-term use in patients with moderately to severely active Crohn’s disease (CD) or ulcerative colitis (UC), without the emergence of new safety signals, a recent study has found.
Excessive and indiscriminate use of proton pump inhibitors (PPIs) may have perilous consequences for patients with chronic hepatitis C virus (HCV) infection, with a recent study showing that such pattern of exposure is associated with increased risks of progression of chronic liver disease to cirrhosis, hepatic decompensation and hepatocellular carcinoma.
The long-term presence of a large volume of acid refluxate appears to be a significant determinant of a reflux episode as chest pain (NCCP), a study has found. Furthermore, the presence of typical reflux symptoms raises the likelihood of reflux being involved in the generation of chest pain.
Both hatha yoga and a low-FODMAP (Fermentable, Oligo-, Di-, Monosaccharides and Polyol) diet can alleviate gastrointestinal symptoms, as well as improve a range of other psychological and physiological health parameters, in patients with irritable bowel syndrome (IBS), a study has shown.
New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.